title: ESAT6 differentially inhibits IFN-γ-inducible class II transactivator isoforms in both a TLR2-dependent and -independent manner.
abstract: Mycobacterium tuberculosis (Mtb) downregulates the surface expression of major histocompatibility class II (MHC II) molecules on macrophages via modulating class II transactivator (CIITA) protein of the host cell. This results in decreased effector function of CD4(+) T cells. In macrophages, CIITA is transcribed by the promoters I (pI) and IV (pIV) and the corresponding gene products are referred to as type I and type IV CIITA, respectively. Earlier studies have mainly focused on CIITA transcribed by pIV; however, these studies also showed that type IV CIITA expression was transient and dispensable for MHC II expression. In the present study, we observed that the Mtb 6-kDa, early secreted antigen (ESAT6) inhibited interferon (IFN)-γ-induced type I as well as type IV CIITA, but, interestingly, inhibition of type I CIITA was found to be independent of Toll-like receptor-2 (TLR2), whereas that of type IV was TLR2 dependent. Moreover, we also present evidence to show that ESAT6-mediated inhibition was regulated via remodeling of the chromatin. We found that ESAT6 caused a decrease in the IFN-γ-stimulated methylation of the histone H3K4, as well as in the levels of histone acetylation at the CIITA pI locus in macrophages. We also found the involvement of mitogen-activated protein kinases ERK1/2 and p38 in the regulation of CIITA by ESAT6. In conclusion, our studies suggest that ESAT6 could inhibit the expression of type I and type IV CIITA through different pathways. Furthermore, ESAT6 could signal through putative receptors other than TLR2, and that the inhibition of IFN-γ-stimulated CIITA by ESAT6 was regulated at the chromatin level.
authors.affiliation: Immunology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
authors.forename: Pavanish
authors.initials: P
authors.lastname: Kumar
authors.forename: Richa
authors.initials: R
authors.lastname: Agarwal
authors.forename: Imran
authors.initials: I
authors.lastname: Siddiqui
authors.forename: Hardeep
authors.initials: H
authors.lastname: Vora
authors.forename: Gobardhan
authors.initials: G
authors.lastname: Das
authors.forename: Pawan
authors.initials: P
authors.lastname: Sharma
mesh_terms: D000942:Antigens, Bacterial / Q000276:immunology / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000276:immunology / Q000494:pharmacology*; D002843:Chromatin / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis; D007371:Interferon-gamma / Q000276:immunology*; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D020033:Protein Isoforms / Q000276:immunology; D015398:Signal Transduction; D051195:Toll-Like Receptor 2 / Q000276:immunology*; D015534:Trans-Activators / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D002843:Chromatin; C093276:ESAT-6 protein, Mycobacterium tuberculosis; D000949:Histocompatibility Antigens Class II; C083728:MHC class II transactivator protein; D009687:Nuclear Proteins; D020033:Protein Isoforms; D051195:Toll-Like Receptor 2; D015534:Trans-Activators; D007371:Interferon-gamma